猪轮状病毒中国分离株JL94 VP7基因的克隆与序列分析

用MA104细胞培养增殖了轮状病毒地方分离株JL94,利用一对根据Genebank中已发表的轮状病毒VP7基因cDNA序列而设计并合成的引物，通过反转录-聚合酶链反应(RT—PCR)从JL94毒株扩增出VP7基因全长cDNA。将其插人pMD18-T载体中，构建了重组质粒pMD18-T—JL94／VP7，并对其进行了Hind Ⅲ，HindⅡ和BamH I的单、双酶切初步鉴定及其核苷酸序列测定，证明克隆的pMD18-T—JL94／VP7为轮状病毒的VP7基因。通过核苷酸序列比较，JL94／VP7与A群猪轮状病毒C134／VP7、OSU／VP7、ICB2185／VP7、YM／VP7核苷酸序列同源性分别为87％、99％、74％和83％。     

鸭肝炎病毒VP1蛋白B细胞抗原表位预测及变异分析

以鸭肝炎病毒(DHV)SN株VP1基因序列为基础,运用Garnier-Robson、Chou-Fasman和Karplus-Schulz方法预测VP1蛋白的二级结构,并分别运用Kyte-Doolittle方法、Jameson-Wolf方法和Emini方法预测蛋白的亲水性、抗原指数和表面可及性,最后结合吴玉章的方法综合分析预测其B细胞抗原表位.结果显示,VP1蛋白C端第132～137、177～186、209～219区段有较好的亲水性、表面可及性和较高的抗原指数,并且在二级结构上含有易形成抗原表位的无规则卷曲和β-转角,可能是VP1蛋白的B细胞抗原优势表位;DHV SN株与弱毒疫苗株在推测的VP1 B细胞抗原表位177～186和209～219两个区域氨基酸序列变异较大.     

联合肌注猪IL2真核质粒对PPV VP2-PCV2 ORF2核酸疫苗免疫效果的影响

将猪IL2基因和PPV VP2基因、PCV2 ORF2截短基因克隆至真核表达载体pCI-neo,构建了重组质粒pCI-ORF2-VP2和pCI-IL2,用脂质体介导法将pCI-ORF2-VP2质粒转染PK15细胞,采用间接免疫荧光法检测在体外的表达情况。并以小鼠为动物模型,将pCI-IL2和pCI-ORF2-VP2质粒联合肌注免疫小鼠,相同剂量免疫2次,间隔2周,同时设立pCI-ORF2-VP2、pCI空载体、猪细小灭活苗、圆环亚单位苗对照,检测免疫小鼠脾脏淋巴细胞的转化功能,外周血T淋巴细胞亚群的动态变化及血清抗体的滴度。结果显示,pCI-ORF2-VP2在PK15细胞中能正常表达,联合免疫组在第28天能够检测到PPV和PCV2抗体,第21~42天诱导淋巴细胞转化和CD4+、CD8+细胞的数量高于或显著高于pCI-ORF2-VP2质粒组。结果表明,猪IL2质粒联合肌注可以提高VP2/ORF2核酸疫苗的免疫效果。     

多型FMDV VP1表位嵌入型载体pMG-SLPMultiVP1的构建及其表达产物鉴定

构建出表达载体pMG-SLPMultiVP1,并对其进行双酶切鉴定及PCR鉴定。将阳性重组质粒转入到发酵乳杆菌中进行表达,并对表达产物进行SDS-PAGE、Western blot和IFAT鉴定。多型FMDV VP1表位嵌入的SLPMultiVP1融合基因成功克隆入穿梭质粒pMG36e中,其表达产物大小约为35ku,部分表达产物位于发酵乳杆菌表面。成功构建了一个乳杆菌嵌入型表达载体pMG-SLPMultiVP1,为以发酵乳杆菌为活菌载体的表位疫苗研究奠定了基础。     

鹅细小病毒四平分离株VP3基因的克隆与序列分析

根据已发表的鹅细小病毒(GPV)核苷酸序列,设计并合成了1对引物,对吉林农业大学预防兽医学研究室分离鉴定的GPV四平株(SP)主要保护性抗原蛋白VP3基因进行扩增。所得到的PCR产物片段大小约1.6 kb,与预期片段大小相符。将该片段纯化后与T载体连接,转化到感受态大肠杆菌JM-109中进行克隆。对所提质粒进行快速鉴定、PCR鉴定以及限制性内切酶NheⅠ和BamHⅠ双酶切鉴定,筛选阳性重组质粒,对重组质粒测序并进行核苷酸序列分析。结果表明:GPV四平株VP3基因长1 605 nt,包含了完整编码GPV VP3蛋白阅读框,且与国内GPV分离株B,GD,HG5/82相应核苷酸序列和氨基酸序列的同源性较高,分别为96.2%,96.3%,96.4%和97.4%,98.7%,98.9%。据此认为,GPV四平株VP3基因可以作为构建具有普遍应用价值的基因工程疫苗的候选基因。     

鸡传染性法氏囊病毒3个毒株VP2高变区的基因扩增与序列分析

以用疫苗株V-hb和V1免疫后又发病的病鸡法氏囊分离毒株HeB-bdI的基因组RNA为模板,利用RT-PCR/Nested-PCR扩增出了cDNA产物.并对其VP2高变区基因序列测定,同时测定了V-hb和V1的基因序列.序列分析表明HeB-bdI毒株与UK661同源性较高为98.4%,而与弱毒株Cu-1、非致病性株PBG98和变异株相差较大;而疫苗株V-hb和V1疫苗株与HeB-bdI毒株的同源性较低仅为93.1%.     

罗氏沼虾白斑综合征病毒囊膜蛋白VP28基因的克隆及分析

根据已公布的罗氏沼虾白斑综合征病毒(WSSV)囊膜蛋白VP28基因序列设计一对特异性引物,从疑似患白斑病毒病的罗氏沼虾(Macrobrachium rosenbergii)中提取总DNA,并以此为模板,经PCR扩增、克隆并测序后将该片段通过GenBank比对,证实为WSSV的VP28基因;与20个已公布的WSSV VP28进行同源性比较,结果显示:从中国对虾、斑节对虾、南美白对虾、日本对虾、波纹龙虾提取的病毒株聚为一类,印度对虾WSSV VP28为另一类,罗氏沼虾WSSV VP28又单独为一类。根据测序结果推测VP28蛋白的二级结构在氨基酸的7～29区间可能为跨膜螺旋区,且该区域高度保守。     

表达鹅细小病毒VP3基因重组腺病毒的构建与鉴定

[目的]构建表达鹅细小病毒 （GPV） VP3基因的重组腺病毒,为机体免疫试验和免疫效果评价奠定基础.[方法]以重组质粒pcDNA-VP3为模板,以GPV-VP3为目的基因,构建GPV-VP3重组腺病毒载体,通过转染获得能稳定表达GPV-VP3基因的重组腺病毒,通过IFA和Western-blot检测GPV-VP3基因的表达情况.[结果]扩增到的GPV-VP3基因全长为1 605 bp,线性化的重组腺病毒穿梭质粒pCR259-VP3能在QBI-HEK293细胞中瞬时表达GPV-VP3基因,表达蛋白的分子量约为60Ku.[结论]该重组腺病毒的构建将为GPV新型疫苗研发和后期体内试验奠定基础.     

A Syndrome Resembling Idiopathic Noncirrhotic Portal Hypertension in 4 Young Doberman Pinschers

We describe 4 young male Doberman Pinschers (3 littermates and 1 unrelated dog) with a syndrome resembling idiopathic or noncirrhotic portal hypertension of humans. Each dog was evaluated for a hepatopathy resulting in portal hypertension, development of portosystemic collateral vessels, and hepatic encephalopathy. These dogs differ from previous reports of young dogs with hepatic insufficiency associated with portal hypertension and acquired portal systemic shunting by their lack of intrahepatic arteriovenous fistulae, portal vein atresia, or intrahepatic fibrosis. Clinicopathologic features included erythrocyte microcytosis, normal to mildly increased liver enzyme activities, increased concentrations of serum bile acids, reduced plasma indocyanine green clearance, and normal total bilirubin concentration. Abdominal ultrasonography disclosed a small liver and portosystemic collateral vessels. Radiographic imaging studies confirmed hepatofugal portal circulation and discounted hepatic arteriovenous fistulae. Histopathologic features in liver tissue from each dog were similar and consistent in all sections examined. Common findings included increased cross-sectional views of hepatic arterioles; hepatic lobular atrophy; scanty increase in connective tissue around some large portal triads; and absence of inflammation, disturbed lobular architecture, bile duct proliferation, or intrahepatic cholestasis.     

Preparation and Identification of Canine Parvovirus NY Strain VP2 Protein Polyclonal Antibody

This study was aimed to prepare canine parvovirus (CPV) VP2 protein polyclonal antibody.The recombinant expression vector pET28a-CPV-VP2 was constructed and transfromed into E.coli BL21 (DE3),the expression of recombinant proteins was induced by IPTG from which the fusion protein was identified by SDS-PAGE.The target protein was purified and emulsify with adjuvant,the prepared immunogen was inoculated into rabbit by subcutaneous injections to prepare of VP2 protein specific polyclonal antibody.The immuno-activity,titers,neutralization titers of the prepared polyclonal antibody were determined by immunoperoxidase monolayer assay (IPMA).The results showed that the expressed recombinant protein VP2 (rVP2) existed in the form of inclusion body with a molecular weight of 72 ku.The prepared polyclonal antibody titer was 1 600 dilution,the virus titer was 10⁷ TCID₅₀/mL,the neutralizing titer was 1∶2 884.The antibodies showed specific reaction with CPV.In conclusion,rVP2 specific polyclonal antibody showed wonderful immunocompetence,specificity and neutralizing activity,providing foundation for the development of genetic vaccine and clinical therapeutic method.